MHC-Restricted Protection of Cats against FIV Infection by Adoptive Transfer of Immune Cells from FIV-Vaccinated Donors

Pu, Ruiyu; Omori, Mayuko; Okada, Susumu; Rine, Stacy L.; Lewis, Barbara; Lipton, Edward; Yamamoto, Janet K.

doi:10.1006/cimm.1999.1574

Cited by 22 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation was also supported by an earlier study which determined high levels of T-cell immunity generated by cats vaccinated with the prototype FIV vaccine [19]. In addition, complete protection against FIV challenge was observed in 36% (4 of 11) of recipients of adoptive transfer with Ab-free peripheral blood mononuclear cells (PBMC) from vaccinated parental donors prior to homologous FIV challenge [18]. Since no vaccine antibodies were transferred, such protection was thought to be mediated by cellular immunity such as antiviral T-cell immunity [19].…”

Section: Introductionsupporting

confidence: 66%

“…Furthermore, this FIV isolate was resistant to vaccine-induced FIV NAbs based on in vitro testing and an in vivo passive-transfer study using vaccine-induced purified antibodies. Hence, the most likely mechanism of such protection was reported to be the vaccine-induced cellular immunity such as T-cell immunity [18–21]. This observation was also supported by an earlier study which determined high levels of T-cell immunity generated by cats vaccinated with the prototype FIV vaccine [19].…”

Section: Introductionmentioning

confidence: 63%

“…The mechanism of such protection was reported to be mediated by an unconventional major histocompatibility complex (MHC)-II restricted CD8 + T-cell immunity rather than anti-SIV NAb immunity [17]. Furthermore, the importance of antiviral T-cell immunity against feline immunodeficiency virus (FIV), the feline counterpart of HIV, has been demonstrated [18–20]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection

Aranyos

Roff

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

The importance of vaccine-induced T-cell immunity in conferring protection with prototype and commercial FIV vaccines is still unclear. Current studies performed adoptive transfer of T cells from prototype FIV-vaccinated cats to partial-to-complete feline leukocyte antigen (FLA)-matched cats a day before either homologous FIVPet or heterologous-subtype pathogenic FIVFC1 challenge. Adoptive-transfer (A–T) conferred a protection rate of 87% (13 of 15, p<0.001) against FIVPet using FLA-matched T cells, whereas all 12 control cats were unprotected. Furthermore, A-T conferred protection rate of 50% (6 of 12, p<0.023) against FIVFC1 using FLA-matched T cells, whereas all 8 control cats were unprotected. Transfer of FLA-matched T and B cells demonstrated that T cells are needed to confer A-T protection. In addition, complete FLA-matching and addition of T-cell numbers >13×106 cells were required for A-T protection against FIVFC1 strain, reported to be a highly pathogenic virus resistant to vaccine-induced neutralizing-antibodies. The addition of FLA-matched B cells alone was not protective. The poor quality of the anti-FIV T-cell immunity induced by the vaccine likely contributed to the lack of protection in an FLA-matched recipient against FIVFC1. The quality of the immune response was determined by the presence of high mRNA levels of cytolysin (perforin) and cytotoxins (granzymes A, B, and H) and T helper-1 cytokines (interferon-γ [IFNγ] and IL2). Increased cytokine, cytolysin and cytotoxin production was detected in the donors which conferred protection in A-T studies. In addition, the CD4+ and CD8+ T-cell proliferation and/or IFNγ responses to FIV p24 and reverse transcriptase increased with each year in cats receiving 1X-3X vaccine boosts over 4 years. These studies demonstrate that anti-FIV T-cell immunity induced by vaccination with a dual-subtype FIV vaccine is essential for prophylactic protection against AIDS lentiviruses such as FIV and potentially HIV-1.

show abstract

Section: Introductionsupporting

confidence: 66%

Section: Introductionmentioning

confidence: 63%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection

Aranyos

Roff

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Characterization of FIV-specific T-cell immunity by adoptive-transfer studies -The first adoptive-transfer studies were performed using MHC-half-matched parents and their progeny (Pu et al, 1999). These studies using single-strain FIV Pet IWV vaccine suggested that recipients of adoptive transfer with peripheral blood cells from vaccinated/ MHC-half-matched cats were more frequently protected against homologous FIV Pet challenge.…”

Section: Vaccine-induced T-cell Immunitymentioning

confidence: 99%

Advances in FIV vaccine technology

Uhl

Martin

Coleman

et al. 2008

Veterinary Immunology and Immunopathology

Self Cite

View full text Add to dashboard Cite

Advances in vaccine technology are occurring in the molecular techniques used to develop vaccines and in the assessment of vaccine efficacy, allowing more complete characterization of vaccine-induced immunity correlating to protection. FIV vaccine development has closely mirrored and occasionally surpassed the development of HIV-1 vaccine, leading to first licensed technology. This review will discuss technological advances in vaccine designs, challenge infection assessment, and characterization of vaccine immunity in the context of the protection detected with prototype and commercial dual-subtype FIV vaccines and in relation to HIV-1.

show abstract

“…Other adoptive transfer studies in animals and humans have evaluated single or multiple infusions using on the order of 10 7 to 10 11 lentivirus or melanoma-specific T-cells, with or without IL-2 administration (Brodie et al, 1999;Brodie et al, 2000;Dudley et al, 2002;Flynn et al, 2005;Ho et al, 1993;Klimas et al, 1994;Mitsuyasu et al, 2000;Pu et al, 1999;Villinger et al, 2002;Walker et al, 2000;Yee et al, 2002). Studies in mice indicate that immune CD4 + T cells are required for survival of infused virus-specific CD8+ T cells (Berger et al, 2000;Hunziker et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: Lack of correlation between in vitro activity and in vivo efficacy

Mealey

Littke

Leib

et al. 2008

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Although CTL are important for control of lentiviruses, including equine infectious anemia virus (EIAV), it is not known if CTL can limit lentiviral replication in the absence of CD4 help and neutralizing antibody. Adoptive transfer of EIAV-specific CTL clones into severe combined immunodeficient (SCID) foals could resolve this issue, but it is not known whether exogenous IL-2 administration is sufficient to support the engraftment and proliferation of CTL clones infused into immunodeficient horses. To address this question we adoptively transferred EIAV Rev-specific CTL clones into four EIAV-challenged SCID foals, concurrent with low-dose aldesleukin (180,000 U/ m 2 ), a modified recombinant human IL-2 (rhuIL-2) product. The dose was calculated based on the specific activity on equine PBMC in vitro, and resulted in plasma concentrations considered sufficient to saturate high affinity IL-2 receptors in humans. Despite specific activity on equine PBMC that was equivalent to recombinant equine IL-2 and another form of rhuIL-2, aldesleukin did not support the engraftment and expansion of infused CTL clones, and control of viral load and clinical disease did not occur. It was concluded that survival of Rev-specific CTL clones infused into EIAVchallenged SCID foals was not enhanced by aldesleukin at the doses used in this study, and that in vitro specific activity did not correlate with in vivo efficacy. Successful adoptive immunotherapy with CTL clones in immunodeficient horses will likely require higher doses of rhuIL-2, co-infusion of CD4+ T lymphocytes, or administration of equine IL-2.

show abstract

MHC-Restricted Protection of Cats against FIV Infection by Adoptive Transfer of Immune Cells from FIV-Vaccinated Donors

Cited by 22 publications

References 33 publications

An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection

An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection

Advances in FIV vaccine technology

Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: Lack of correlation between in vitro activity and in vivo efficacy

Contact Info

Product

Resources

About